Immunity to asexual blood stage malaria and vaccine approaches

Immunology and Cell Biology

Volumn 80, Issue 5, 2002, Pages 401-414

  Wipasa, J ^a   Elliott, S ^b   Xu, H ^a   Good, M F ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

Asexual blood stage; Malaria; Vaccine

Indexed keywords

ADJUVANT; APICAL MEROZOITE SURFACE ANTIGEN 1; ERYTHROCYTE MEMBRANE PROTEIN 1; GAMMA INTERFERON; GLYCOSYLPHOSPHATIDYLINOSITOL; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MALARIA VACCINE; MEMBRANE ANTIGEN; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 2; N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE; RHOPTRY ASSOCIATED PROTEIN 1; RHOPTRY ASSOCIATED PROTEIN 2; RING INFECTED ERYTHROCYTE SURFACE ANTIGEN; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELLULAR IMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; ENDEMIC DISEASE; HUMAN; IMMUNIZATION; LIFE CYCLE; MALARIA; MEROZOITE; MORTALITY; NONHUMAN; PARASITE TRANSMISSION; PLASMODIUM; PROTEIN EXPRESSION; TH1 CELL; TH2 CELL;

PROTOZOA;

EID: 0036378078     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1711.2002.01107.x     Document Type: Article

References (162)

1. Breman JG. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am. J. Trop. Med. Hyg. 2001; 64: 1-11.
2. WHO. The World Health Report. Geneva: 1999; 49.
3. Fujioka H, Masamichi A. The malaria parasite and its life cycle. In: Wahlgren M, Perlmann P, (eds) Malaria; Molecular and Clinical Aspects. Amsterdam: Harwood Academic Publishers, 1999; 19.
4. Dondorp AM, Kager PA, Vreeken J, White NJ. Abnormal blood flow and red blood cell deformability in severe malaria. Parasitol. Today 2000; 16: 228.
5. Clark IA, Schofield L. Pathogenesis of malaria. Parasitol. Today 2000; 16: 451.
6. Baird JK. Age-dependent characteristics of protection v. susceptibility to Plasmodium falciparum. Ann. Trop. Med. Parasitol. 1998; 92: 367.
7. Andrysiak PM, Collins WE, Campbell GH. Stage-specific and species-specific antigens of Plasmodium vivax and Plasmodium ovale defined by monoclonal antibodies. Infect. Immun. 1986; 54: 609.
8. Fandeur T, Chalvet W. Variant- and strain-specific immunity in Saimiri infected with Plasmodium falciparum. Am. J. Trop. Med. Hyg. 1998; 58: 225.
9. Rotman HL, Daly TM, Long CA. Plasmodium immunization with carboxyl-terminal regions of MSP-1 protects against homologous but not heterologous blood-stage parasite challenge. Exp. Parasitol. 1999; 91: 78.
10. Bull PC, Lowe BS, Kortok M, Molyneux CS, Newbold CI, Marsh K. Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Natl Med. 1998; 4: 358.
11. Spencer Valero LM, Ogun SA, Fleck SL et al. Passive immunization with antibodies against three distinct epitopes on Plasmodium yoelii merozoite surface protein 1 suppresses parasitemia. Infect. Immun. 1998; 66: 3925.
12. Narum DL, Ogun SA, Thomas AW, Holder AA. Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethalPlasmodium yoelii yoelii YM blood-stage infection. Infect. Immun. 2000; 68: 2899.
13. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J. Exp. Med. 1990; 172: 1633.
14. von der Weid T, Honarvar N, Langhorne J. Gene-targeted mice lacking B cells are unable to eliminate a blood stage malaria infection. J. Immunol. 1996; 156: 2510.
15. Langhorne J, Cross C, Seixas E, Li C, von der Weid T. A role for B cells in the development of T cell helper function in a malaria infection in mice. Proc. Natl Acad. Sci. USA 1998; 95: 1730.
16. Taylor-Robinson AW, Phillips RS. B cells are required for the switch from Th1- to Th2-regulated immune responses to Plasmodium chabaudi chabaudi infection. Infect. Immun. 1994; 62: 2490.
17. Piper KP, Hayward RE, Cox MJ, Day KP. Malaria transmission and naturally acquired immunity to PfEMP-1. Infect. Immun. 1999; 67: 6369.
18. Chizzolini C, Dupont A, Akue JP et al. Natural antibodies against three distinct and defined antigens of Plasmodium falciparum in residents of a mesoendemic area in Gabon. Am. J. Trop. Med. Hyg. 1988; 39: 150.
19. Astagneau P, Roberts JM, Steketee RW, Wirima JJ, Lepers JP, Deloron P. Antibodies to a Plasmodium falciparum blood-stage antigen as a tool for predicting the protection levels of two malaria-exposed populations. Am. J. Trop. Med. Hyg. 1995; 53: 23.
20. Egan AF, Blackman MJ, Kaslow DC. Vaccine efficacy of recombinant Plasmodium falciparum merozoite surface protein 1 in malaria-naive-exposed, and/or -rechallenged Aotus vociferans monkeys. Infect. Immun. 2000; 68: 1418.
21. 19) induces protective immunity to blood stage malaria infection in mice. Parasite Immunol. 1998; 20: 413.
22. Hirunpetcharat C, Tian JH, Kaslow DC et al. Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen-specific antibody titer, but not with effector CD4+ T cells. J. Immunol. 1997; 159: 3400.
23. Aucan C, Traore Y, Fumoux F, Rihet P. Familial correlation of immunoglobulin G subclass responses to Plasmodium falciparum antigens in Burkina Faso. Infect. Immun. 2001; 69: 996.
24. Aribot G, Rogier C, Sarthou JL et al. Pattern of immunoglobulin isotype response to Plasmodium falciparum blood-stage antigens in individuals living in a holoendemic area of Senegal (Dielmo, west Africa). Am. J. Trop. Med. Hyg. 1996; 54: 449.
25. Bouharoun-Tayoun H, Druilhe P. Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. Infect. Immun. 1992; 60: 1473.
26. Aucan C, Traore Y, Tall Fet al. High immunoglobulin G2 (IgG2) and low IgG4 levels are associated with human resistance to Plasmodium falciparum malaria. Infect. Immun. 2000; 68: 1252.
27. Matsumoto S, Yukitake H, Kanbara H, Yamada H, Kitamura A, Yamada T. Mycobacterium bovis bacillus calmette-guerin induces protective immunity against infection by Plasmodium yoelii at blood-stage depending on shifting immunity toward Th1 type and inducing protective IgG2a after the parasite infection. Vaccine 2000; 19: 779.
28. Su Z, Stevenson MM. Central role of endogenous gamma interferon in protective immunity against blood-stage Plasmodium chabaudi AS infection. Infect. Immun. 2000; 68: 4399.
29. Smith NC, Favila-Castillo L, Monroy-Ostria A, Hirunpetcharat C, Good MF. The spleen, IgG antibody subsets and immunity to Plasmodium berghei in rats. Immunol. Cell Biol. 1997; 75: 318.
30. Vukovic P, Hogarth PM, Barnes N, Kaslow DC, Good MF. Immunoglobulin G3 antibodies specific for the 19-kilodalton carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein 1 transfer protection to mice deficient in Fc-gammaRI receptors. Infect. Immun. 2000; 68: 3019.
31. Majarian WR, Daly TM, Weidanz WP, Long CA. Passive immunization against murine malaria with an IgG3 monoclonal antibody. J. Immunol. 1984; 132: 3131.
32. Tebo AE, Kremsner PG, Luty AJ. Plasmodium falciparum: a major role for IgG3 in antibody-dependent monocyte-mediated cellular inhibition of parasite growth in vitro. Exp. Parasitol. 2001; 98: 20.
33. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J. Exp. Med. 1995; 182: 409.
34. Perraut R, Mercereau-Puijalon O, Mattei D et al. Induction of opsonizing antibodies after injection of recombinant Plasmodium falciparum vaccine candidate antigens in preimmune Saimiri sciureus monkeys. Infect. Immun. 1995; 63: 554.
35. Ramasamy R, Rajakaruna R. Association of malaria with inactivation of alpha1, 3-galactosyl transferase in catarrhines. Biochim. Biophys. Acta. 1997; 1360: 241.
36. Giribaldi G, Ulliers D, Mannu F, Arese P, Turrini F. Growth of Plasmodium falciparum induces stage-dependent haemichrome formation, oxidative aggregation of band 3, membrane deposition of complement and antibodies, and phagocytosis of parasitized erythrocytes. Br. J. Haematol. 2001; 113: 492.
37. Blackman MJ, Scott-Finnigan TJ, Shai S, Holder AA. Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein. J. Exp. Med. 1994; 180: 389.
38. Blackman MJ, Heidrich H-G, Donachie S, McBride JS, Holder AA. A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibitory antibodies. J. Exp. Med. 1990; 172: 379.
39. Lyon JA, Carter JM, Thomas AW, Chulay JD. Merozoite surface protein-1 epitopes recognized by antibodies that inhibit Plasmodium falciparum merozoite dispersal. Mol. Biochem. Parasitol. 1997; 90: 223.
40. Smith JD, Craig AG, Kriek Net al. Identification of a Plasmodium falciparum intercellular adhesion molecule-1 binding domain: a parasite adhesion trait implicated in cerebral malaria. Proc. Natl Acad. Sci. USA 2000; 97: 1766.
41. Michon P, Fraser T, Adams JH. Naturally acquired and vaccine-elicited antibodies block erythrocyte cytoadherence of the Plasmodium vivax Duffy binding protein. Infect. Immun. 2000; 68: 3164.
42. David PH, Hommel M, Miller LH, Udeinya IJ, Oligino LD. Parasite sequestration in Plasmodium falciparum malaria: spleen and antibody modulation of cytoadherence of infected erythrocytes. Proc. Natl Acad. Sci. USA 1983; 80: 5075.
43. Carlson J, Holmquist G, Taylor DW, Perlmann P, Wahlgren M. Antibodies to a histidine-rich protein (PfHRP1) disrupt spontaneously formed Plasmodium falciparum erythrocyte rosettes. Proc. Natl Acad. Sci. USA 1990; 87: 2511.
44. Ramasamy R, Ramasamy M, Yasawardena S. Antibodies and Plasmodium falciparum merozoites. Trends Parasitol. 2001; 17: 194.
45. Ramasamy R, Yasawardena S, Kanagaratnam R., Buratti E, Baralle FE, Ramasamy MS. Antibodies to a merozoite surface protein promote multiple invasion of red blood cells by malaria parasites. Parasite Immunol. 1999; 21: 397.
46. Guevara Patino JA, Holder AA, McBride JS, Blackman MJ. Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies. J. Exp. Med. 1997; 186: 1689.
47. Marsh K, Howard RJ. Antigens induced on erythrocytes by P. falciparum: expression of diverse and conserved determinants. Science 1986; 231: 150.
48. Newbold CI, Pinches R, Roberts DJ, Marsh K. Plasmodium falciparum: the human agglutinating antibody response to the infected red cell surface is predominantly variant specific. Exp. Parasitol. 1992; 75: 281.
49. Biggs BA, Gooze L, Wycherley K et al. Antigenic variation in Plasmodium falciparum. Proc. Natl Acad. Sci. USA 1991; 88: 9171.
50. Su XZ, Heatwole VM, Wertheimer SP et al. The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of Plasmodium falciparum-infected erythrocytes. Cell 1995; 82: 89.
51. Smith JD, Chitnis CE, Craig AG et al. Switches in expression of Plasmodium falciparum var genes correlate with changes in antigenic and cytoadherent phenotypes of infected erythrocytes. Cell 1995; 82: 101.
52. Baruch DI, Gormely JA, Ma C, Howard RJ, Pasloske BL. Plasmodium falciparum erythrocyte membrane protein 1 is a parasitized erythrocyte receptor for adherence to CD36, thrombospondin, and intercellular adhesion molecule 1. Proc. Nat Acad. Sci. USA 1996; 93: 3497.
53. Reeder JC, Cowman AF, Davern KM et al. The adhesion of Plasmodium falciparum-infected erythrocytes to chondroitin sulfate A is mediated by P. falciparum erythrocyte membrane protein 1. Proc. Natl Acad. Sci. USA 1999; 96: 5198.
54. Roberts DJ, Craig AG, Berendt AR et al. Rapid switching to multiple antigenic and adhesive phenotypes in malaria. Nature 1992; 357: 689.
55. Biggs BA, Anders RF, Dillon HE et al. Adherence of infected erythrocytes to venular endothelium selects for antigenic variants of Plasmodium falciparum. J. Immunol. 1992; 149: 2047.
56. Giha HA, Staalsoe T, Dodoo D et al. Nine-year longitudinal study of antibodies to variant antigens on the surface of Plasmodium falciparum-infected erythrocytes. Infect. Immun. 1999; 67: 4092.
57. Bull PC, Kortok M, Kai O et al. Plasmodium falciparum-infected erythrocytes: agglutination by diverse Kenyan plasma is associated with severe disease and young host age. J. Infect. Dis. 2000; 182: 252.
58. Bull PC, Lowe BS, Kortok M, Marsh K. Antibody recognition of Plasmodium falciparum erythrocyte surface antigens in Kenya: evidence for rare and prevalent variants. Infect. Immun. 1999; 67: 733.
59. Gamain B, Miller LH, Baruch DI. The surface variant antigens of Plasmodium falciparum contain cross-reactive epitopes. Proc. Natl Acad. Sci. USA 2001; 98: 2664.
60. Baruch DI, Ma XC, Singh HB, Bi X, Pasloske BL, Howard RJ. Identification of a region of PfEMP1 that mediates adherence of Plasmodium falciparum infected erythrocytes to CD36: conserved function with variant sequence. Blood 1997; 90: 3766.
61. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383: 787.
62. Bruna-Romero O, Rodriguez A. Dendritic cells can initiate protective immune responses against malaria. Infect. Immun. 2001; 69: 5173.
63. Chemtai AK, Hamers-Casterman C, Hamers R, De Baetselier P. T cell-mediated immunity in murine malaria. II. Induction of protective immunity to P. chabaudi by antigen-fed macrophages and antigen-educated lymphocytes. Parasite Immunol. 1984; 6: 469.
64. van der Heyde HC, Huszar D, Woodhouse C, Manning DD, Weidanz WP. The resolution of acute malaria in a definitive model of B cell deficiency, the JHD mouse. J. Immunol. 1994; 152: 4557.
65. Stevenson MM, Tam MF. Differential induction of helper T cell subsets during blood-stage Plasmodium chabaudi AS infection in resistant and susceptible mice. Clin. Exp. Immunol. 1993; 92: 77.
66. Taylor-Robinson AW, Phillips RS. Infective dose modulates the balance between Th1- and Th2-regulated immune responses during blood-stage malaria infection. Scand. J. Immunol. 1998; 48: 527.
67. Fell AH, Currier J, Good MF. Inhibition of Plasmodium falciparum growth in vitro by CD4+ and CD8+ T cells from non-exposed donors. Parasite Immunol. 1994; 16: 579.
68. Carvalho LH, Fontes CJ, Krettli AU. Cellular responses to Plasmodium falciparum major surface antigens and their relationship to human activities associated with malaria transmission. Am. J. Trop. Med. Hyg. 1999; 60: 674.
69. Migot-Nabias F, Luty AJ, Ringwald P et al. Immune responses against Plasmodium falciparum asexual blood-stage antigens and disease susceptibility in Gabonese and Cameroonian children. Am. J. Trop. Med. Hyg. 1999; 61: 488.
70. Winkler S, Willheim M, Baier K et al. Reciprocal regulation of Th1- and Th2-cytokine-producing T cells during clearance of parasitemia in Plasmodium falciparum malaria. Infect. Immun. 1998; 66: 6040.
71. Amante FH, Good MF. Prolonged Th1-like response generated by a Plasmodium yoelii-specific T cell clone allows complete clearance of infection in reconstituted mice. Parasite Immunol. 1997; 19: 111.
72. Hirunpetcharat C, Finkelman F, Clark IA, Good MF. Malaria parasite-specific Th1-like T cells simultaneously reduce parasitemia and promote disease. Parasite Immunol. 1999; 21: 319.
73. Hermsen CC, Mommers E, van de Wiel T, Sauerwein RW, Eling WM. Convulsions due to increased permeability of the blood-brain barrier in experimental cerebral malaria can be prevented by splenectomy or anti-T cell treatment. J. Infect. Dis. 1998; 178: 1225.
74. Sayles PC, Rakhmilevich L. Exacerbation of Plasmodium chabaudi malaria in mice by depletion of TCR alpha beta+ T cells, but not TCR gamma delta+ T cells. Immunology 1996; 87: 29.
75. Seixas EM, Langhorne J. gammadelta T cells contribute to control of chronic parasitemia in Plasmodium chabaudi infections in mice. J. Immunol. 1999; 162: 2837.
76. Langhorne J, Mombaerts P, Tonegawa S. Alpha beta and gamma delta T cells in the immune response to the erythrocytic stages of malaria in mice. Int. Immunol. 1995; 7: 1005.
77. Nakazawa S, Brown AE, Maeno Y, Smith CD, Aikawa M. Malaria-induced increase of splenic gamma delta T cells in humans, monkeys, and mice. Exp. Parasitol. 1994; 79: 391.
78. Troye-Blomberg M, Worku S, Tangteerawatana P et al. Human gamma delta T cells that inhibit the in vitro growth of the asexual blood stages of the Plasmodium falciparum parasite express cytolytic and proinflammatory molecules. Scand. J. Immunol. 1999; 50: 642.
79. Gazzinelli RT. Molecular and cellular basis of interleukin 12 activity in prophylaxis and therapy against infectious diseases. Mol. Med. Today 1996; 2: 258.
80. Sam H, Stevenson MM. In vivo IL-12 production and IL-12 receptors beta1 and beta2 mRNA expression in the spleen are differentially up-regulated in resistant B6 and susceptible A/J mice during early blood-stage Plasmodium chabaudi AS malaria. J. Immunol. 1999; 162: 1582.
81. Sam H, Stevenson MM. Early IL-12 p70, but not p40, production by splenic macrophages correlates with host resistance to blood-stage Plasmodium chabaudi AS malaria. Clin. Exp. Immunol. 1999; 117: 343.
82. Yoshimoto T, Yoneto T, Waki S, Nariuchi H. Interleukin-12-dependent mechanisms in the clearance of blood-stage murine malaria parasite Plasmodium berghei XAT, an attenuated variant of P. berghei NK65. J. Infect. Dis. 1998; 177: 1674.
83. Mohan K, Moulin P, Stevenson MM. Natural killer cell cytokine production, not cytotoxicity, contributes to resistance against blood-stage Plasmodium chabaudi AS infection. J. Immunol. 1997; 159: 4990.
84. Choudhury HR, Sheikh NA, Bancroft GJ, Katz DR, De Souza JB. Early nonspecific immune responses and immunity to blood-stage nonlethal Plasmodium yoelii malaria. Infect. Immun. 2000; 68: 6127.
85. Luty AJ, Perkins DJ, Lell B et al. Low interleukin-12 activity in severe Plasmodium falciparum malaria. Infect. Immun. 2000; 68: 3909.
86. Seder RA, Gazzinelli R, Sher A, Paul WE. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc. Natl Acad. Sci. USA 1993; 90: 10188.
87. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994; 76: 241.
88. Ockenhouse CF, Schulman S, Shear HL. Induction of crisis forms in the human malaria parasite Plasmodium falciparum by gamma-interferon-activated, monocyte-derived macrophages. J. Immunol. 1984; 133: 1601.
89. Luty AJ, Lell B, Schmidt-Ott R, et al. Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in young African children. J. Infect. Dis. 1999; 179: 980.
90. Yoneto T, Yoshimoto T, Wang CR et al. Gamma interferon production is critical for protective immunity to infection with blood-stage Plasmodium berghei XAT but neither NO production nor NK cell activation is critical. Infect. Immun. 1999; 67: 2349.
91. Balmer P, Alexander J, Phillips RS. Protective immunity to erythrocytic Plasmodium chabaudi AS infection involves IFN gamma-mediated responses and a cellular infiltrate to the liver. Parasitology 2000; 121: 473.
92. Perkins DJ, Weinberg JB, Kremsner PG. Reduced interleukin-12 and transforming growth factor-beta1 in severe childhood malaria: relationship of cytokine balance with disease severity. J. Infect. Dis 2000; 182: 988.
93. Stevenson MM, Tam MF, Wolf SF, Sher A. IL-12-induced protection against blood-stage Plasmodium chabaudi AS requires IFN-gamma and TNF-alpha and occurs via a nitric oxide-dependent mechanism. J. Immunol. 1995; 155: 2545.
94. Pichyangkul S, Saengkrai P, Webster HK. Plasmodium falciparum pigment induces monocytes to release high levels of tumor necrosis factor-alpha and interleukin-1 beta. Am. J. Trop. Med. Hyg. 1994; 51: 430.
95. Schofield L, Hackett F. Signal transduction in host cells by a glycosylphosphatidylinositol toxin of malaria parasites. J. Exp. Med. 1993; 177: 145.
96. Jacobs P, Radzioch D, Stevenson MM. A Th1-associated increase in tumor necrosis factor alpha expression in the spleen correlates with resistance to blood-stage malaria in mice. Infect. Immun. 1996; 64: 535.
97. Butcher GA, Clark IA. The inhibition of Plasmodium falciparum growth in vitro by sera from mice infected with malaria or treated with TNF. Parasitology 1990; 101: 321.
98. Haidaris CG, Haynes JD, Meltzer MS, Allison AC. Serum containing tumor necrosis factor is cytotoxic for the human malaria parasite Plasmodium falciparum. Infect. Immun. 1983; 42: 385.
99. Muniz-Junqueira MI, dos Santos-Neto LL, Tosta CE. Influence of tumor necrosis factor-alpha on the ability of monocytes and lymphocytes to destroy intraerythrocytic Plasmodium falciparum in vitro. Cell Immunol. 2001; 208: 73.
100. Grau GE, Heremans H, Piguet PF et al. Monoclonal antibody against interferon gamma can prevent experimental cerebral malaria and its associated overproduction of tumor necrosis factor. Proc. Natl Acad. Sci. USA 1989; 86: 5572.
101. Jacobs P, Radzioch D, Stevenson MM. In vivo regulation of nitric oxide production by tumor necrosis factor alpha and gamma interferon, but not by interleukin-4, during blood stage malaria in mice. Infect. Immun. 1996; 64: 44.
102. Grau GE, Taylor TE, Molyneux ME et al. Tumor necrosis factor and disease severity in children with falciparum malaria. N. Engl. J. Med. 1989; 320: 1586.
103. Brown H, Turner G, Rogerson S et al. Cytokine expression in the brain in human cerebral malaria. J. Infect. Dis. 1999; 180: 1742.
104. Kremsner PG, Winkler S, Brandts C et al. Prediction of accelerated cure in Plasmodium falciparum malaria by the elevated capacity of tumor necrosis factor production. Am. J. Trop. Med. Hyg. 1995; 53: 532.
105. Vouldoukis I, Mazier D, Debre P, Mossalayi MD. Nitric oxide and human infectious diseases. Res. Immunol. 1995; 146: 689.
106. Taylor-Robinson AW, Phillips RS, Severn A, Moncada S, Liew FY. The role of Th1 and Th2 cells in a rodent malaria infection. Science 1993; 260: 1931.
107. Bank TW. Malaria at a Glance. Roll Back Malaria. 2001. Report available at URL: http://mosquito.who.int
108. Good MF, Doolan DL. Immune effector mechanisms in malaria. Curr. Opin. Immunol. 1999; 11: 412.
109. McBride JS, Heidrich HG. Fragments of the polymorphic Mr 185,000 glycoprotein from the surface of isolated Plasmodium falciparum merozoites form an antigenic complex. Mol. Biochem. Parasitol. 1987; 23: 71.
110. Thomas AW, Carr DA, Carter JM, Lyon JA. Sequence comparison of allelic forms of the Plasmodium falciparum merozoite surface antigen MSA2. Mol. Biochem. Parasitol. 1990; 43: 211.
111. Huber W, Felger I, Matile H, Lipps HJ, Steiger S, Beck HP. Limited sequence polymorphism in the Plasmodium falciparum merozoite surface protein 3. Mol. Biochem. Parasitol. 1997; 87: 231.
112. Wang L, Black CG, Marshall VM, Coppel RL. Structural and antigenic properties of merozoite surface protein 4 of Plasmodium falciparum. Infect. Immun. 1999; 67: 2193.
113. Marshall VM, Tieqiao W, Coppel RL. Close linkage of three merozoite surface protein genes on chromosome 2 of Plasmodium falciparum. Mol. Biochem. Parasitol. 1998; 94: 13.
114. Trucco C, Fernandez-Reyes D, Howell S et al. The merozoite surface protein 6 gene codes for a 36 kDa protein associated with the Plasmodium falciparum merozoite surface protein-1 complex. Mol. Biochem. Parasitol. 2001; 112: 91.
115. Pachebat JA, Ling IT, Grainger Met al. The 22 kDa component of the protein complex on the surface of Plasmodium falciparum merozoites is derived from a larger precursor, merozoite surface protein 7. Mol. Biochem. Parasitol. 2001; 117: 83.
116. Black CG, Wu T, Wang L, Hibbs AR, Coppel RL. Merozoite surface protein 8 of Plasmodium falciparum contains two epidermal growth factor-like domains. Mol. Biochem. Parasitol. 2001; 114: 217.
117. Holder AA, Guevara Patino JA, Uthaipibull C et al. Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria. Parassitologia 1999; 41: 409.
118. Lyon JA, Geller RH, Haynes JD, Chulay JD, Weber JL. Epitope map and processing scheme for the 195,000-dalton surface glycoprotein of Plasmodium falciparum merozoites deduced from cloned overlapping segments of the gene. Proc. Natl Acad. Sci. USA 1986; 83: 2989.
119. Holder AA, Sandhu JS, Hillman Y et al. Processing of the precursor to the major merozoite surface antigens of Plasmodium falciparum. Parasitology 1987; 94: 199.
120. Blackman MJ, Holder AA. Secondary processing of the Plasmodium falciparum merozoite surface protein-1 (MSP1) by a calcium-dependent membrane-bound serine protease: shedding of MSP133 as a noncovalently associated complex with other fragments of the MSP1. Mol. Biochem. Parasitol. 1992; 50: 307.
121. Blackman MJ, Whittle H, Holder AA. Processing of the Plasmodium falciparum major merozoite surface protein-1: identification of a 33-kilodalton secondary processing product which is shed prior to erythrocyte invasion. Mol. Biochem. Parasitol. 1991; 49: 35.
122. Blackman MJ, Ling IT, Nicholls SC, Holder AA. Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains. Mol. Biochem. Parasitol. 1991; 49: 29.
123. Holder AA, Freeman RR. Immunization against blood-stage rodent malaria using purified parasite antigens. Nature 1981; 294: 361.
124. Siddiqui WA, Tam LQ, Kramer KJ et al. Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria. Proc. Natl Acad. Sci. USA 1987; 84: 3014.
125. Nikodem D, Davidson E. Identification of a novel antigenic domain of Plasmodium falciparum merozoite surface protein-1 that specifically binds to human erythrocytes and inhibits parasite invasion in vitro. Mol. Biochem. Parasitol. 2000; 108: 79.
126. Tian JH, Kumar S, Kaslow DC, Miller LH. Comparison of protection induced by immunization with recombinant proteins from different regions of merozoite surface protein 1 of Plasmodium yoelii. Infect. Immun. 1997; 65: 3032.
127. Perera KL, Handunnetti SM, Holm I, Longacre S, Mendis K. Baculovirus merozoite surface protein 1 C-terminal recombinant antigens are highly protective in a natural primate model for human Plasmodium vivax malaria. Infect. Immun. 1998; 66: 1500.
128. Kumar S, Collins W, Egan A et al. Immunogenicity and efficacy in aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1. Infect. Immun. 2000; 68: 2215.
129. Ling IT, Ogun SA, Holder AA. Immunization against malaria with a recombinant protein. Parasite Immunol. 1994; 16: 63.
130. Daly TM, Long CA. Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria. J. Immunol. 1995; 155: 236.
131. O'Donnell RA, de Koning-Ward TF, Burt RA et al. Antibodies against merozoite surface protein (MSP 1): are a major component of the invasion-inhibitory response in individuals immune to malaria. J. Exp. Med. 2001; 193: 1403.
132. Shi YP, Sayed U, Qari SH et al. Natural immune response to the C-terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1. Infect. Immun. 1996; 64: 2716.
133. 19 - a study in immune adults living in areas of Plasmodium falciparum transmission. Am. J. Trop. Med. Hyg. 2001; 64: 204.
134. Rotman HL, Daly TM, Clynes R, Long CA. FC receptors are not required for antibody-mediated protection against lethal malaria challenge in a mouse model. J. Immunol. 1998; 161: 1908.
135. Hirunpetcharat C, Vukovic P, Liu XQ, Kaslow DC, Miller LH, Good MF. Absolute requirement for an active immune response involving B cells and Th cells in immunity to Plasmodium yoelii passively acquired with antibodies to the 19-kDa carboxyl-terminal fragment of merozoite surface protein-1. J. Immunol. 1999; 162: 7309.
136. Ling IT, Ogun SA, Holder AA. The combined epidermal growth factor-like modules of Plasmodium yoelii merozoite surface protein-1 are required for a protective immune response to the parasite. Parasite Immunol. 1995; 17: 425.
137. Tian JH, Good MF, Hirunpetcharat C et al. Definition of T cell epitopes within the 19 kDa carboxylterminal fragment of Plasmodium yoelii merozoite surface protein 1 (MSP1 (19) and their role in immunity to malaria. Parasite Immunol. 1998; 20: 263.
138. Tian JH, Miller LH, Kaslow DC et al. Genetic regulation of protective immune response in congenic strains of mice vaccinated with a subunit malaria vaccine. J. Immunol. 1996; 157: 1176.
139. Uthaipibull C, Aufiero B, Syed SE et al. Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum. J. Mol. Biol. 2001; 307: 1381.
140. Berzins K, Ander RF. The malaria antigens. In: Wahlgren M, Perlmann P, (eds) Malaria; Molecular and Clinical Aspects. Amsterdam, Netherlands: Harwood Academic Publishers, 1999; 181.
141. Crewther PE, Matthew ML, Flegg RH, Anders RF. Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes. Infect. Immun. 1996; 64: 3310.
142. Amante FH, Crewther PE, Anders RF, Good MF. A cryptic T cell epitope on the apical membrane antigen 1 of Plasmodium chabaudi adami can prime for an anamnestic antibody response: implications for malaria vaccine design. J. Immunol. 1997; 159: 5535.
143. Xu H, Hodder AN, Yan H, Crewther PE, Anders RF, Good MF. CD4+ T cells acting independently of antibody contribute to protective immunity to Plasmodium chabaudi infection after apical membrane antigen 1 immunization. J. Immunol. 2000; 165: 389.
144. Collins WE, Pye D, Crewther PE et al. Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. Am. J. Trop. Med. Hyg. 1994; 51: 711.
145. Kocken CH, Dubbeld MA, Van Der Wel A et al. High-level expression of Plasmodium vivax apical membrane antigen 1 (AMA-1) in Pichia pastoris: strong immunogenicity in Macaca mulatta immunized with P. vivax AMA-1 and adjuvant SBAS2. Infect. Immun. 1999; 67: 43.
146. Hodder AN, Crewther PE, Anders RF. Specificity of the protective antibody response to apical membrane antigen 1. Infect. Immun. 2001; 69: 3286.
147. Anders RF, Saul A. Malaria vaccines. Parasitol. Today 2000; 16: 444.
148. Howard RF, Jacobson KC, Rickel E, Thurman J. Analysis of inhibitory epitopes in the Plasmodium falciparum rhoptry protein RAP-1 including identification of a second inhibitory epitope. Infect. Immun. 1998; 66: 380.
149. Collins WE, Walduck A, Sullivan JS et al. Efficacy of vaccines containing rhoptry-associated proteins RAP1 and RAP2 of Plasmodium falciparum in Saimiri Boliviensis monkeys. Am. J Trop. Med. Hyg. 2000, 62: 466.
150. Fievet N, Maubert B, Cot M et al. Humoral and cellular immune responses to synthetic peptides from the Plasmodium falciparum blood-stage antigen, Pf155/RESA, in Cameroonian women. Clin. Immunol. Immunopathol. 1995; 76: 164.
151. Wahlin Flyg B, Siddique AB, Perlmann P, Esposito F, Berzins K. Inhibition of in vitro growth of Plasmodium falciparum field isolates mediated by human antibodies to Pf155/RESA and Pf332. Parasite Immunol. 1999; 21: 331.
152. Snounou G, Jarra W, Preiser PR. Malaria multigene families. the price of chronicity. Parasitol. Today 2000; 16: 28.
153. Englund PT. The structure and biosynthesis of glycosyl phosphatidylinositol protein anchors. Annu. Rev. Biochem. 1993; 62: 121.
154. Naik RS, Branch OH, Woods AS et al. Glycosylphosphatidylinositol anchors of Plasmodium falciparum: molecular characterization and naturally elicited antibody response that may provide immunity to malaria pathogenesis. J. Exp. Med. 2000; 192: 1563.
155. Playfair JH, Taverne J, Bate CA, de Souza JB. The malaria vaccine: anti-parasite or anti-disease? Immunol. Today 1990; 11: 25.
156. Genton B, Al-Yaman F, Anders R et al. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. Vaccine 2000; 18: 2504.
157. Saul A, Lawrence G, Smillie A et al. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine 1999; 17: 3145.
158. Rogers WO, Baird JK, Kumar A et al. Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques. Infect. Immun. 2001; 69: 5565.
159. Cox JC, Coulter AR. Adjuvants - a classification and review of their modes of action. Vaccine 1997; 15: 248.
160. Daly TM, Long CA. Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection. Infect. Immun. 1996; 64: 2602.
161. Hui GS, Hashimoto CN. Pathways for potentiation of immunogenicity during adjuvant-assisted immunizations with Plasmodium falciparum major merozoite surface protein 1. Infect. Immun. 1998; 66: 5329.
162. Hagen TL, Sulzer AJ, Kidd MR, Lal AA, Hunter RL. Role of adjuvants in the modulation of antibody isotype, specificity, and induction of protection by whole blood-stage Plasmodium yoelii vaccines. J. Immunol. 1993; 151: 7077.